Literature DB >> 20391511

Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index.

Raphaèle Seror1, Xavier Mariette, Simon Bowman, Gabriel Baron, Jacques Eric Gottenberg, Hendrika Bootsma, Hendrika Boostma, Elke Theander, Athanasios Tzioufas, Claudio Vitali, Philippe Ravaud.   

Abstract

OBJECTIVE: To assess and compare the sensitivity to change of the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) with that of other primary Sjögren's syndrome (SS) disease activity indexes.
METHODS: We abstracted 96 patient profiles, including data on 3 successive visits (visits 1-3), from the medical charts of patients with primary SS. Patient profiles were scored with the ESSDAI, SS Disease Activity Index (SSDAI), and Sjögren's Systemic Clinical Activity Index (SCAI). Thirty-nine experts assessed 5 profiles for whether disease activity had improved, worsened, or remained stable at visits 2 and 3.
RESULTS: For improved patients, the standardized response means (SRMs) for all scores did not differ, and ranged from -1.08 to -1.38 between visits 1 and 2 and from -0.50 to -0.76 between visits 2 and 3. For patients with worsened activity, the SRMs between visits 1 and 2 and between visits 2 and 3 were +0.46 and +1.10 for the ESSDAI, -0.03 and +0.79 for the SSDAI, and +0.17 and +1.02 for the SCAI, respectively. For patients with stable activity, the SRMs between visits 1 and 2 and between visits 2 and 3 were 0.00 and -0.13 for the ESSDAI, -0.44 and -0.11 for the SSDAI, and -0.36 and +0.34 for the SCAI, respectively.
CONCLUSION: For patients with improved activity, the 3 disease activity indexes showed similar, large sensitivity to change. However, the ESSDAI seemed to detect changes in activity more accurately than other disease activity indexes. Notably, for patients with stable activity, the ESSDAI did not show erroneous improvement.

Entities:  

Mesh:

Year:  2010        PMID: 20391511     DOI: 10.1002/acr.20173

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  10 in total

1.  Latest advances in connective tissue disorders.

Authors:  Vijay Rao; Simon Bowman
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 2.  Sjögren syndrome: looking forward to the future.

Authors:  Sara Zandonella Callegher; Ivan Giovannini; Sabine Zenz; Valeria Manfrè; Martin H Stradner; Alojzija Hocevar; Marwin Gutierrez; Luca Quartuccio; Salvatore De Vita; Alen Zabotti
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-23       Impact factor: 3.625

Review 3.  Sjögren's syndrome in older patients: aetiology, diagnosis and management.

Authors:  Rada V Moerman; Hendrika Bootsma; Frans G M Kroese; Arjan Vissink
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

4.  2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts.

Authors:  Caroline H Shiboski; Stephen C Shiboski; Raphaèle Seror; Lindsey A Criswell; Marc Labetoulle; Thomas M Lietman; Astrid Rasmussen; Hal Scofield; Claudio Vitali; Simon J Bowman; Xavier Mariette
Journal:  Arthritis Rheumatol       Date:  2016-10-26       Impact factor: 10.995

5.  Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.

Authors:  Katrine Brække Norheim; Erna Harboe; Lasse G Gøransson; Roald Omdal
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

6.  Clinical Characteristics and Outcome of Primary Sjogren's Syndrome: A Large Asian Indian Cohort.

Authors:  Pulukool Sandhya; Lakshmanan Jeyaseelan; Robert Hal Scofield; Debashish Danda
Journal:  Open Rheumatol J       Date:  2015-06-26

7.  Effectiveness of Traditional Chinese Medicine Compound JieDuTongLuoShengJin Granules Treatment in Primary Sjögren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Ben Li; Jiaqi Hou; Yue Yang; Xuemei Piao; Yueying Chen; Luan Xue; Dan Wang; Jiandong Hu; Guoling Li; Xiangxiang Wu; Yu Sun; Runa Jin
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-10       Impact factor: 2.629

8.  Decreased Bilirubin is Associated With Disease Activity of Primary Sjögren's Syndrome.

Authors:  Jing Xie; Zhencheng Zhang; Yan Liang; Zaixing Yang
Journal:  Arch Rheumatol       Date:  2020-01-08       Impact factor: 1.472

Review 9.  EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide.

Authors:  Raphaèle Seror; Simon J Bowman; Pilar Brito-Zeron; Elke Theander; Hendrika Bootsma; Athanasios Tzioufas; Jacques-Eric Gottenberg; Manel Ramos-Casals; Thomas Dörner; Philippe Ravaud; Claudio Vitali; Xavier Mariette; Karsten Asmussen; Soren Jacobsen; Elena Bartoloni; Roberto Gerli; Johannes Wj Bijlsma; Aike A Kruize; Stefano Bombardieri; Arthur Bookman; Cees Kallenberg; Petra Meiners; Johan G Brun; Roland Jonsson; Roberto Caporali; Steven Carsons; Salvatore De Vita; Nicoletta Del Papa; Valerie Devauchelle; Alain Saraux; Anne-Laure Fauchais; Jean Sibilia; Eric Hachulla; Gabor Illei; David Isenberg; Adrian Jones; Menelaos Manoussakis; Thomas Mandl; Lennart Jacobsson; Frederic Demoulins; Carlomaurizio Montecucco; Wan-Fai Ng; Sumusu Nishiyama; Roald Omdal; Ann Parke; Sonja Praprotnik; Matjia Tomsic; Elizabeth Price; Hal Scofield; Kathy L Sivils; Josef Smolen; Roser Solans Laqué; Serge Steinfeld; Nurhan Sutcliffe; Takayuki Sumida; Guido Valesini; Valeria Valim; Frederick B Vivino; Cristina Vollenweider
Journal:  RMD Open       Date:  2015-02-20

10.  Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren's syndrome.

Authors:  Hideki Nakamura; Toshimasa Shimizu; Yukinori Takagi; Yoshiko Takahashi; Yoshiro Horai; Yoshikazu Nakashima; Shuntaro Sato; Hirokazu Shiraishi; Tatsufumi Nakamura; Junya Fukuoka; Takashi Nakamura; Atsushi Kawakami
Journal:  BMC Musculoskelet Disord       Date:  2015-11-04       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.